Of Interest

Post treatment discontinuation, most centers conduct imaging every 3 months during the first year of remission.

Five-year recurrence-free survival was 55.1% with nevus-associated acral melanoma (NAAM) vs. 42.3% with de novo acral melanoma (DNAM).

Vusolimogene oderparepvec plus nivolumab showed responses and a favorable safety profile in advanced melanoma post-anti–PD-1 therapy, per phase 2 IGNYTE trial data.

Data augmentation techniques like cropping and blurring allow AI models to overcome limited datasets, improving skin cancer detection rates.